RxDoctor Payments Data

Yudith Crawford

Family · El Paso, TXNPI 1326758962

Payments from drug & device makers

$3,831in general payments, 2019–2025

Across 169 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$573
  • AbbVie$420
  • Neurocrine Biosciences, Inc.$304
  • Inspire Medical Systems, Inc.$283
  • SK Life Science, Inc.$203
  • Novartis$190
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$3,74198%
  • Education$902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,831 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate21$37,941
BriviactBrivaracetam18$37,102
RexultiBrexpiprazole18$27,662
UbrelvyUbrogepant13$24,616
QuliptaAtogepant16$19,598
BotoxOnabotulinumtoxina15$19,158
Aimovig AutoinjectorErenumab-Aooe25$17,767
OngentysOpicapone15$16,787
Lacosamide41$15,881
XcopriCenobamate13$15,436
Memantine Hcl403$7,149
Levetiracetam70$3,360
AmantadineAmantadine Hcl32$3,226
Oxcarbazepine56$2,981
Pregabalin33$2,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$420$63,37144 claims
PfizerNurtec Odt$93$37,94121 claims
UCB, Inc.Briviact$573$37,10218 claims
Neurocrine Biosciences, Inc.Ongentys$304$16,78715 claims
SK Life Science, Inc.Xcopri$203$15,43613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →